OBI 999
Alternative Names: Globo H ADC; OBI-999Latest Information Update: 18 Jan 2024
Price :
$50 *
At a glance
- Originator OBI Pharma
- Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Immunotoxins; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 05 Jan 2024 OBI Pharma terminates a phase I/II clinical trials in Solid tumours (Late-stage disease) in USA and Taiwan (IV, Infusion) due to failure to achieve therapeutic potential (NCT04084366)
- 14 Apr 2023 Pharmacodynamics data from preclinical trials in Solid tumours presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 03 Jun 2022 Efficacy, safety and pharmacokinetic data from a phase I part of phase I/II trial in Solid tumours presented at the 58th Annual Meeting of the American Society of Clinical Oncology (ASC0-2022)